Dyslipidemia
Conditions
Keywords
Dyslipidemia, Target cholesterol, Undertreatment
Brief summary
The purpose of this study is to establish the proportion of Bulgarian patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Fourth Joint European Task Force guidelines.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks * Signed Informed Consent
Exclusion criteria
* Informed Consent not provided
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number and percentage of patients achieving the LDL-C goals, according to the Fourth Joint European Task Force guidelines | 6 months - one visit only, no follow-up visits |
Secondary
| Measure | Time frame |
|---|---|
| The number and percentage of subjects achieving the LDL-C goals, according to the Fourth Joint European Task Force guidelines for several subject subsets | 6 months - one visit only, no follow-up visits |
| The number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III / 2004 updated 2004 NCEP ATP III guidelines, overall and for several subject subsets | 6 months - one visit only, no follow-up visits |
| The number and percentage of subjects achieving the non HDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III/national guidelines [<130mg/dL (3,37mmol/L)], in the following sub-population: patients with fasting triglycerides >200 mg/dL | 6 months - one visit only, no follow-up visits |
Countries
Bulgaria
Outcome results
None listed